Abstract
This work was carried out to evaluate the antibacterial activity of new series of 5-hydrazono[1,2,4]triazoloquinazolines (1-34). Antibacterial activity of the target molecules was tested against a variety of species of Gram-positive bacteria as Bacillus anthracis (RCMB 0100162-8), B. subtilis (RCMB 0100169-3), Enterococcus faecalis (RCMB 0100154-2), Staphylococcus aureus (RCMB 0100183-9), S. epidermidis (RCMB 0100183-9), Streptococcus pyogenes (RCMB 0100172-5), S. bovis (RCMB 0100174-4), Micrococcus luteus (RCMB 0100132-2), and methicillin-resistant Staphylococcus aureus MRSA (RCMB 0100194-5) in addition to different Gram-negative bacteria as Serratia marcescens (RCMB 01002 72.6), Salmonella enterica serovar Typhi (RCMB 0100215-4), Proteus mirabilis (RCMB 0100254-2), Klebsiella oxytoca (RCMB 0100283-4), Enterobacter cloacae (RCMB 0100264-5), Citrobacter freundii (RCMB 0100263-6), Pseudomonas aeruginosa (RCMB 0100243-5), Escherichia coli (RCMB 010052-6) and Mycobacterium tuberculosis (RCMB 010094-8). Broth double dilution method was employed to examine the potential antibacterial activity against the aforementioned bacteria. The minimum inhibitory concentration (MIC) of investigated compounds was reported in mu g/mL. Ampicillin and vancomycin were used as reference drugs in case of Gram-positive bacteria and gentamicin was used with Gram-negative bacteria, whereas isoniazid was used with M. tuberculosis. Results revealed that compounds 6, 11, 13, 19, 21, 24, 27, 30 and 34 exhibited remarkable significant broad spectrum antibacterial activity against most of the examined Gram-positive and five strains of Gram-negative bacteria. Compounds 6, 13 and 27 showed activity similar to vancomycin on MRSA bacteria, while compound 27 demonstrated remarkable effect against M. tuberculosis with respect to isoniazid.